How much can J&J make of Yondelis' long-sought FDA approval?

After years of setbacks, Johnson & Johnson's ($JNJ) Yondelis finally has its shot at some U.S. sales. The drug won its sought-after FDA approval Friday--not in ovarian cancer as previously hoped, but as a treatment for soft-tissue sarcoma, which otherwise has few treatment options. Just what the FDA nod means in terms of sales remains to be seen--more than a decade ago, it was pegged as a potential blockbuster--but if the European market is any indication, uptake won't break any records. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.